Incyte Biosciences Shanghai Co., Ltd.

The primary objective is to determine the efficacy of INCB000928 in inhibiting the occurrence of new heterotopic ossification in FOP subjects. The key secondary objective is to evaluate the efficacy of INCB000928 in reducing disease attacks and improving symptoms associated with disease attacks. Secondary objectives include evaluating the safety and tolerability of INCB000928 for the treatment of FOP subjects; confirming the efficacy of INCB000928 in subjects randomized to the placebo group during the double-blind period at week 48; characterizing the PK of INCB000928; and further evaluating the efficacy of INCB000928 in FOP subjects.